Interpretation of marijuana-positive urine tests requires an understanding of the excretion pattern of marijuana metabolites in humans. However, limited urinary excretion data from controlled clinical studies of marijuana use are available. In this study, six subjects smoked a single marijuana cigarette (placebo, 1.75% Ag-tetrahydrocannabinol [THC], or 3.55% THC) each week while residing on the clinical ward of the Addiction Research Center. Individual urine specimens were collected for 7 days after drug administration and analyzed for 11-nor-9-carboxy-A%tetrahydrocannabinol (THCCOOH) by gas chromatography-mass spectrometry (GC-MS) with a limit of detection of 0.5 ng/mL. Substantial intersubject variability in patterns of THCCOOH excretion was noted between subjects and between doses. Mean THCCOOH concentrations in the first urine collections were 47 • 22.3 ng/mL and 75.3 • 48.9 ng/mL after the 1.75 and 3.55% THC cigarettes, respectively. Mean peak urine THCCOOH concentrations averaged 89.8 • 31.9 ng/mL and 153.4 • 49.2 ng/mL after smoking of approximately 15.8 mg and 33.8 mg THC, respectively. The mean times of peak urine concentration were 7.7 • 0.8 h after the 1.75% THC and 13.9 • 3.5 h after the 3.55% THC dose. Mean GC-MS THCCOOH detection times for the last positive urine sample after the smoking of a single 1.75 or 3.55% THC cigarette were 33.7 • 9.2 h and 88.6 • 9.5 h, respectively, when a 15-ng/mL cutoff concentration was used. An average of 93.9 • 24.5 pg THCCOOH (range, 34.6-171.6 pg) was excreted by each subject during the 7-day period after smoking of a single 1.75% THC cigarette. The average amount of THCCOOH excreted in the same time period after the high dose was 197.4 • 33.6 pg (range, 107.5-305.0 pg). This represented an average of only 0.54 • 0.14% and 0.53 • 0.09% of the original amount of THC in the low-and high-dose cigarettes, respectively. These data provide a detailed compilation of THCCOOH concentrations in urine after administration of marijuana that may aid in the interpretation of urine cannabinoid results.
Introduction
Interpretation of marijuana-positive urine tests requires an understanding of the excretion pattern of marijuana metabolites in humans. However, limited urinary excretion data from controlled clinical studies of marijuana use are available. In this study, six subjects smoked a single marijuana cigarette (placebo, 1.75% Ag-tetrahydrocannabinol [THC], or 3.55% THC) each week while residing on the clinical ward of the Addiction Research Center. Individual urine specimens were collected for 7 days after drug administration and analyzed for 11-nor-9-carboxy-A%tetrahydrocannabinol (THCCOOH) by gas chromatography-mass spectrometry (GC-MS) with a limit of detection of 0.5 ng/mL. Substantial intersubject variability in patterns of THCCOOH excretion was noted between subjects and between doses. Mean THCCOOH concentrations in the first urine collections were 47 • 22.3 ng/mL and 75.3 • 48.9 ng/mL after the 1.75 and 3.55% THC cigarettes, respectively. Mean peak urine THCCOOH concentrations averaged 89.8 • 31.9 ng/mL and 153. 4 • 49.2 ng/mL after smoking of approximately 15.8 mg and 33.8 mg THC, respectively. The mean times of peak urine concentration were 7.7 • 0.8 h after the 1.75% THC and 13.9 • 3.5 h after the 3.55% THC dose. Mean GC-MS THCCOOH detection times for the last positive urine sample after the smoking of a single 1.75 or 3.55% THC cigarette were 33.7 • 9.2 h and 88.6 • 9.5 h, respectively, when a 15-ng/mL cutoff concentration was used. An average of 93.9 • 24.5 pg THCCOOH (range, 34.6-171.6 pg) was excreted by each subject during the 7-day period after smoking of a single 1.75% THC cigarette. The average amount of THCCOOH excreted in the same time period after the high dose was 197. 4 • 33.6 pg (range, 107.5-305.0 pg). This represented an average of only 0.54 • 0.14% and 0.53 • 0.09% of the original amount of THC in the low-and high-dose cigarettes, respectively. These data provide a detailed compilation of THCCOOH concentrations in urine after administration of marijuana that may aid in the interpretation of urine cannabinoid results.
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Marijuana has been self-administered for its psychoactive effects for many centuries. Currently, it is the most highly used illicit substance in the United States. Consequently, more positive urine tests for cannabinoids are obtained than for any other drug class in civilian and military workplace drug-testing programs. Drug treatment and rehabilitation clinics, forensic investigations, and emergency toxicology departments generate additional positive test results. In each of these venues, an understanding of excretion of marijuana metabolites in humans is needed so that urine test results can be interpreted. Unfortunately, little urinary excretion data from controlled clinical studies of marijuana use are available to guide interpretation.
Detailed excretion studies of cannabinoids in urine are limited because controlled clinical studies are difficult and expensive to perform. Clinical studies must be performed in a manner that limits access to additional drugs that can confound study results (1) . Historically, this has required confinement of subjects to restrict drug access or use of radiolabeled drug to differentiate between the administered dose and unauthorized drug use (2, 3) . Detailed excretion studies also require the analysis of large numbers of individual urine samples. Attempts to reduce the number of required analyses include combining specimens into 12-or 24-h pools or reducing the period of collection or both (4) (5) (6) (7) . In some studies, individual measurements were made but only mean excretion data were presented (8) . The advantage of measurement of drug or metabolites or both in each urine specimen and in each individual is the additional information one obtains. Presenting each subject's complete excretion profile allows one to calculate useful parameters, such as minimum and maximum windows of detection, peak concentration, intersubject variability, and total amount of drug excreted.
The method of measurement of urinary cannabinoids also influences analytical findings. Marijuana research performed in the 1970s and 1980s frequently used less sensitive and less specific methods of analysis. The Syva EMIT TM d.a.u. | 20-ng/mL immunoassay, which exhibited cross-reactivity to a wide variety of marijuana metabolites, was used in many of the studies on urinary cannabinoid excretion (8, 9) . Other data were collected with proprietary and commercial radioimmunoassays and enzyme immunoassays of varying sensitivities and specificities. The sensitivities and specificities of these assays have changed over time, which limits comparison of current test results with previously obtained data (10) . The development of gas chromatographic-mass spectrometric (GC-MS) methods has provided the capability for sensitive and specific measurement of 11-nor-9-carboxy-Ag-tetrahydrocannabinol (THCCOOH).
This study characterizes the urinary excretion profiles of THCCOOH in six healthy male subjects after single, shortterm, smoked doses of marijuana. The subjects were restricted to a closed clinical ward and monitored throughout the study to prevent unauthorized drug use. All urine specimens were collected for 7 days after marijuana smoking and analyzed for THCCOOH by GC-MS. Individual excretion profiles and mean excretion parameters were determined.
Experimental Subjects
Six healthy male subjects with a history of marijuana use resided on the clinical ward of the Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health while participating in a protocol designed to characterize the pharmacokinetics and pharmacodynamics of short-term marijuana smoking. The protocol was approved by the Francis Scott Key Medical Center Institutional Review Board and adhered to federal guidelines for the conduct of research on drugs of abuse in human subjects. All subjects provided written informed consent, were under continuous medical supervision, and were financially compensated for their participation. Subject characteristics and history of drug use were previously published (10) . In brief, the men ranged from 28 to 36 years of age, had an average weight of 77.6 kg, and had a mean percent body fat content of 14.7%. Subjects began marijuana smoking between 13 and 16 years of age and smoked between 0.4 and 7.9 marijuana cigarettes per week (mean, 2.3 cigarettes). Subjects resided on the ward for approximately 1 week before drug administration. Studies were not initiated until a minimum of five consecutive daily negative urine test results were achieved for drugs of abuse, including cannabiholds as measured by the Syva EMIT 100-ng/mL immunoassay, and until subjects' baseline scores on performance tests stabilized. Admittance to the clinical ward was restricted to prevent access to unauthorized licit or illicit drugs. In addition, frequent random urine drug tests were performed to deter additional drug exposures.
Subjects, medical staff, and investigators were blind to the order in which marijuana doses were administered. Marijuana cigarettes, assayed for THC content, were obtained from the Research Technology Branch, National Institute on Drug Abuse. Baseline measures, including urine samples, were obtained 30-60 rain before drug administration for each experimental session. Marijuana smoking was computer-paced. The number of cigarette puffs, the length of time of each inhalation, the time between puffs, and the puff hold time were controlled to reduce intersubject variability, but the depth of each inhalation was not controlled. Subjects remained within the research area for approximately 3 h after drug administration while undergoing extensive monitoring. Data collection, including collection of all urine specimens, continued for 168 h.
Specimens
Each individual urine specimen was collected from the six research subjects throughout the 3-week study. Specimens (N = 957) were collected in polypropylene containers and refrigerated immediately after urination. The volume of each specimen was measured. Urine specimens were stored in 30-mL polypropylene screw-cap bottles at -30~ on the day of collection. After the 7-month protocol was complete, frozen specimens were assembled, coded, and randomized. This procedure ensured that all specimens were randomized for analysis within the large batch to eliminate any potential bias based on subject, dose, time of collection, and individual calibration. Each specimen was analyzed under blind conditions for THCCOOH by GC-MS with a one-point calibration at I5 ng/mL and a 0.5-ng/mL limit of detection according to a previously published procedure (11) . A modified Jaffe method on a Hitachi 704 automated clinical analyzer (Boehringer Mannheim Corp., Indianapolis, IN) was used to obtain urine creatinine concentrations. Specimens were thawed just before analysis and subjected to a single freeze-thaw cycle. Quality control samples were included within the randomized batch and served to assure within-and between-batch reproducibility.
Results

Urine THCCOOH excretion profiles
THCCOOH concentrations by GC-MS for six subjects who smoked two doses of marijuana are shown in Table I , together with the volume of each urine collection and the creatinine concentration. Subjects produced an average of 43.7 _+ 4.6 (mean plus or minus standard error of the mean) urine specimens (range, 28-59) and 44.5 +_ 6.3 urine specimens (range, 32-69) during the 7 days after the low-dose (1.75% THC) and high-dose (3.55% THC) cigarettes, respectively. THCCOOH was still detectable (0.5-ng/mL cutoff) in all subjects' urine specimens at the end of the 7-day collection period. Substantial intersubject variability in the patterns of THCCOOH excretion was noted between subjects and between doses.
THCCOOH concentration in the first urine specimen Figure 1 illustrates individual THCCOOH concentrations measured in each subject's first urine specimen ( Figure 1A) and the time of collection of first voids ( Figure 1B ). Except for subject B, THCCOOH concentrations were found to be doserelated; mean concentrations were 47 + 22.3 ng/mL and 75.3 • 48.9 ng/mL after the 1.75 and 3.55% THC cigarettes, respectively. The range of THCCOOH concentrations in first urine specimens was 5.5-138.4 ng/mL after the low-dose cigarette and 9.1-318 ng/mL after the high-dose cigarette. The mean time of the first urine specimen was 3.7 • 0.6 h and 3.0 • 0.5 h for the low and high doses, respectively. Times of collection ranged from 2.2 to 6.5 h after the low-close and from 1 to 4 h after the high-dose conditions. Fifty percent of the subjects' first urine specimens after the low dose and 83% of the first urine specimens after the high dose were positive by GC-MS (15-ng/mL THCCOOH cutoff concentration).
Peak urinary THCCOOH excretion
Mean peak urine THCCOOH concentrations averaged 89.8 • 31.9 ng/mL and 153.4 • 49.2 ng/mL after smoking of approximately ]5.8 mg THC (1.75% THC dose) and 33.8 mg THC (3.55% THC dose), respectively ( Figure 2A ). Although peak concentrations appeared to be dose-related, there was a 12-fold variation between individuals. Peak concentrations ranged from 20.6 to 234.2 ng/mL after the low-dose cigarette and from 29.9 to 355.2 ng/mL after the high-dose cigarette. All subjects, except subject E, had higher peak THCCOOH concentrations after the high-dose exposure compared with the low-dose exposure. The time of peak urine THCCOOH concentration was also dose-related; the mean was 7.7 • 0.8 h after the ].75% THC dose and 13.9 • 3.5 h after the 3.55% THC dose ( Figure 2B ). For two individuals (subjects B and E), the peak THCCOOH concentration for the high dose occurred at an earlier time than that observed for the low dose. The times of peak excretion in the six subjects ranged from 6 to 11.3 h and from 5.6 to 28 h after the low and high doses, respectively. Subject G was unusual in that his peak THCCOOH concentration of 223.2 ng/mL was collected 20.5 h after the high-dose exposure. Subject F's highest urine THCCOOH concentration was measured in a specimen collected 28 h after drug administration; however, a lower peak concentration was attained (52.5 ng/mL).
THCCOOH detection times
During the terminal elimination phase, consecutive urine specimens fluctuated between positive or negative as THCCOOH concentrations approached the cutoff concentration of the GC-MS assay (15 ng/mL). Therefore, two different windows of drug detection were determined: a detection time for consecutive positive urine specimens and a detection time for the last positive urine specimen ( Figure 3 ). Mean THC-COOH detection times for the last consecutive positive specimen were 28.7 • 10.8 h (range, 8.0-68.5 h) and 39.0 • 13.0 h (range, 4.0-68.5 h) for the low-and high-dose conditions, respectively. After smoking the low marijuana dose, three of six subjects had additional positive urine samples interspersed between negative urine samples. This had the effect of producing much longer detection times for the last positive specimen. All six subjects had substantially longer detection times for the last positive urine specimen as compared with the last consecutive positive specimen after the high marijuana dose. Subject F produced only a single positive urine sample at 8 h after the low dose, and although the first urine specimen was positive at 4 h after the high-dose condition, urine specimens at 5.0, 8.8, and 11.0 h were less than 15 ng/mL THCCOOH. Of the 13 urine specimens produced by subject F from 20 h through 57 h after drug administration, only one at 30 h was below the 15-ng/mL cutoff.
Mean GC-MS THCCOOH detection times for the last positive urine sample after the smoking of a single 1.75 or 3.55% THC cigarette were 33.7 • 9.2 h and 88.6 • 9.5 h, respectively, when a 15-ng/mL cutoff concentration was used. Substantial variability was noted in the range of detection time between subjects: 8-68.5 h after the low dose and 57-122.3 h after the high dose. The mean number of urine specimens containing more than 15 ng/mL THCCOOH was 6.3 • 1.7 and ranged from 1 to 11 for the six subjects after the low dose. Substantially higher numbers of positive urine specimens were produced after the high dose; there were 14.7 • 1.1 positive urine specimens (range, 12-20 positive urine specimens). Three of six subjects produced negative urine specimens at the time of their first urination after the 1.75% THC cigarette, whereas only subject G's first urine specimen contained less than 15 ng/mL THCCOOH after smoking the 3.55% THC cigarette. In general, THCCOOH detection time windows by GC-MS were substantially longer after the high dose as compared with the low dose.
Percent dose and absolute amount of THCCOOH excreted
An average of 93.9 • 24.5 pg THCCOOH (range, 34.6--171.6 IJg) was excreted by each subject during the 7-day period after smoking of a single 1.75% THC cigarette ( Figure 4A ). The average amount of THCCOOH excreted in the same time period after the high dose was 197.4 + 33.6 pg (range, 107.5-305.0 pg). This represents an average of only 0.54 • 0.14% and 0.53 + 0.09% of the original amount of THC in the low-and high-dose cigarettes, respectively ( Figure 4B ). Respective ranges of percent dose excreted were 0.20-0.99% (low dose) and 0.29-0.82% (high dose). When expressed as a percent of the original dose, the low-and high-dose mean values were similar. This was true for four individuals but not for the other two subjects. The extremes are exemplified by subject B, who excreted a higher percentage of THC after the low-dose cigarette (0.97% after the 1.75% THC cigarette; 0.54% after the 3.55% THC cigarette), and subject G, who excreted almost twice the percentage of THC after the high-dose cigarette (0.43% after the 1.75% THC cigarette; 0.82% after the 3.55% THC cigarette) as compared with the low-dose cigarette.
Discussion
The smoking route provides a rapid and highly efficient method of delivery of the primary psychoactive component of marijuana, THC. Because of its high lipophilicity, THC accumulates in fat tissue as a function of the amount and frequency of smoking and as a function of marijuana potency. Detectable levels of THC were found in fat biopsy specimens obtained ' THC = A'~-Tetrahydrocannabinol. ' Elapsed time after initiation of drug administration. THCCOOH = l l-Nor-9-carboxy-A'J-tetrahyclrocannabinol. * THC = Ag-Tetrahydrocannabinol.
~" Elapsed time after initiation of drug administration. THCCOOH = 1 t-Nor-9-carboxy-Ag-tetrahydrocannabinol. 
~" Elapsed time after initiation of drug administration. * THCCOOH = 11 -Nor-9-carboxy-Ag-tetrahydracannabinol.
more than 4 weeks after marijuana smoking (12) . The redistribution of THC from tissue to blood was demonstrated to be the rate-limiting step in its metabolism (13) . THC is rapidly metabolized to the inactive metabolite, THCCOOH, and to numerous other cannabinoids, primarily by cytochrome P450 enzymes in the liver and other tissues (14) . Most of the THC-COOH is conjugated and excreted as the water-soluble glucuronic acid. Wall et al. (15) were the first to demonstrate that THCCOOH was the primary cannabinoid metabolite excreted in the urine; 15-20% ofa THC dose was eliminated as acidic urinary metabolites, whereas approximately 65% was excreted in the feces as 11-hydroxy-A9-THC and THCCOOH (13) . Of the 15-20% of the dose eliminated as acidic urinary metabolites, it was estimated that 27% was conjugated and unconjugated THCCOOH (16) . The present study details excretion of THCCOOH in urine during a period of 7 days in six healthy male subjects who smoked 1.75% THC (low dose) and 3.55% THC (high dose) cigarettes. A total of 957 urine specimens were analyzed for THCCOOH by GC-MS. The concentration of THCCOOH in the first specimen after smoking marijuana was evaluated to determine how rapidly the metabolite appeared in urine; however, this study was not specifically designed to address this concern. Subjects were encouraged to delay urination for the initial 3 h after smoking because of intensive monitoring of pharmacodynamic parameters during this time period. Consequently, the first specimens may have been more concentrated than would be expected because of the imposed delay in urination. No other information was found in the literature on THCCOOH concentrations of first urine specimens analyzed by GC-MS. The THCCOOH concentration in first urine specimens increased with the THC dose, except for subject B. The time that elapsed before subject B produced his first urine specimen was substantially different for the low (6.5 h) and high (3.4 h) doses and may account for this apparent discrepancy. The THCCOOH concentration in the first urine specimen appeared to be dependent on the relative potency of the marijuana cigarette, the elapsed time after drug administration, smoking efficiency, and individual differences in drug metabolism and excretion. Mean peak urine THCCOOH concentrations (89.8 and 153.4 ng/mL) were consistent with the finding of a mean of 71 ng/mL 7 h after the smoking of one 2.8% THC cigarette (17) . Kelly and Jones (6) reported a mean peak THCCOOH concentration of 55.5 ng/mL in the first daily 24-h urine collection after intravenous administration of 5 mg THC. Kemp et al. (7) reported a mean peak THCCOOH concentration of approximately 180 ng/mL at 6 h after one 3.58% THC cigarette was smoked. Drug detection time, or the time after drug administration that an individual tests positive, is an important factor in the interpretation of urine drug-testing results. Detection time is dependent on pharmacological factors (e.g., drug dose, route of administration, and rates of metabolism and excretion) and
Journal of Analytical Toxicology, Vol. 20, October 1996 analytical factors (e.g., assay sensitivity, specificity, and accuracy). In the present study, the 15-ng/mL GC-MS cutoff for THCCOOH was chosen for evaluation because of its required use in Department of Health and Human Services and Department of Transportation-regulated laboratories and in military drug-testing facilities. Mean detection times of smoked marijuana varied considerably between subjects despite attempts to standardize marijuana dosing with a computer-paced smoking protocol. Mean THCCOOH detection times of 33.7 and 88.6 h after the low and high doses, respectively, were in agreement with other reports of mean detection times of up to 3 days in infrequent and up to 4 days in frequent drug users after injection of a 5-rag intravenous THC dose (6) . GC-MS detection times were shorter than those obtained with less specific immunoassays. Law et al. (4) measured cannabinoid metabolites in 24-h urine pools by radioimmunoassay for 12 days after oral administration of 20 mg THC. Individual case studies from drug-treatment programs report fluctuating positive and negative test results for consecutively collected urine specimens late in the excretion timeline; most results were generated with a 20-ng/mL immunoassay (8, 18, 19) . In the present study, GC-MS detection times for the last positive urine specimen were found to be moderately increased after the low dose and substantially increased after the high dose when compared with detection times for the last consecutive positive specimen. The percentage of THC excreted by subjects during the 7-day monitoring period was less than 1% of the THC initially present in the marijuana cigarettes. These percentages represent only a small fraction (0.20-0.99%) of the available dose, that is, 15.8 and 33.8 mg for the 1.75 and 3.55% THC cigarettes, respectively. The small percentage of the total dose found in the urine as THCCOOH is not surprising considering the many factors that influence THCCOOH excretion after marijuana smoking. Before harvesting, cannabis plant material contains little active THC (20) . When marijuana is smoked, THC carboxylic acids spontaneously decarboxylate to produce THC, and there is nearly complete conversion on heating. Pyrolysis of THC during smoking destroys approximately 31% of the drug (21) . Drug availability is further reduced by loss of drug in sidestream smoke. Agurell et al. (16) estimated that the systemic availability of smoked THC is approximately 18% and has a range of 10-14% for light users and 23-27% for heavy marijuana users. In the present study, use of the paced smoking protocol did not permit consumption of the entire marijuana cigarette. The major route of excretion of THC and metabolites is in the feces (65%) rather than in the urine (20%) (14) . In addition, numerous cannabinoid metabolites are known to be produced through human metabolism of THC. THC bioavailability is reduced because of the combined effect of these factors; the actual available dose is much lower than the amount of THC and THC precursor present in the marijuana cigarette.
In summary, urinary excretion of the primary marijuana metabolite, THCCOOH, was documented in six male subjects for 7 days after smoking of a single 1.75 or 3.55% THC marijuana cigarette using a sensitive GC-MS method. Wide intersubject variability was noted in the THCCOOH concentrations in the first and peak urine specimens, in the detection times of the last consecutive positive specimen and the last positive specimen, and in the amount of THCCOOH and percentage of THC dose excreted during 7 days. These data provide a detailed compilation of THCCOOH concentrations in urine after administration of marijuana that should aid in the interpretation of urine cannabinoid results. 
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